Investor Presentaiton
R&D investor presentation
Icodec, a once-weekly insulin, is designed to raise the
innovation-bar through better control and convenience
Steady state pharmacodynamic profile of insulin
icodec suitable for once-weekly dosing
Glucose infusion rate
(mg/kg/min)
5
4
3
2
180
0
9
The phase 2 trial compared once-weekly icodec to
once-daily insulin glargine
Icodec (weekly) + metformin + DPP-4i
(+ daily placebo)
Insulin glargine U100 (daily) + metformin + DPP-4i
(+weekly placebo)
Primary endpoint
Change in HbA1c from baseline to week 26
Secondary endpoints
•
Change in FPG, body weight and SMBG
Weekly insulin dose during the last two weeks of treatment
Hypoglycaemic episodes
Icodec
247 people
with type 2
diabetes
Once-daily insulin treatment
2
4
Time (days)
*Steady-state levels of predicted profiles based on modelled phase 1 data.
6
PK: Pharmacokinetics; FPG: Fasting plasma glucose; SMBG: Self monitoring blood glucose
Note: Insulin icodec is the international non-proprietary name
novo nordiskView entire presentation